| DATE: September 4, 2024 | | |
| --- | --- | --- |
| **TOPIC** | **DISCUSSION/ACTION** | **FOLLOW-UP** |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a poll link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. |  |
| CPIC UGT1A1/irinotecan Guideline | Kelly requested authors for the upcoming CPIC UGT1A1/irinotecan (and possibly other cancer medications) guideline with expertise in this area. Of special need are authors in countries outside of the USA and in pediatrics. | Email Kelly ([kelly.caudle@stjude.org](mailto:kelly.caudle@stjude.org)) if you would like to self-nominate or nominate a colleague |
| PharmVar Update | Andrea Gaedigk, PhD, Children’s Mercy Kansas City, gave an update on the Pharmacogene Variation Consortium (PharmVar), a central repository for pharmacogene (PGx) variation that focuses on haplotype structure and allelic variation. Slides attached with minutes. |  |
| Impact of Pharmacist Collaborative Practice Agreement on Pharmacogenomic Implementation for Patients Referred from Geriatric Medicine | Rachel Larmer, PharmD, MB, Cleveland Clinic presented. Paper in review so slides will not be available. |  |